Ocular Therapeutix, Inc. (OCUL) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 1 Strong Buy, 15 Buy, 2 Hold.
The consensus price target is $25.50 (low: $21.00, high: $30.00), representing an upside of 191.1% from the current price $8.76.
Analysts estimate Earnings Per Share (EPS) of $-1.18 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.22 vs est $-1.18 (missed -3.4%). 2025: actual $-1.42 vs est $-1.45 (beat +2.3%). Analyst accuracy: 97%.
OCUL Stock — 12-Month Price Forecast
$25.50
▲ +191.10% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Ocular Therapeutix, Inc., the average price target is $25.50, with a high forecast of $30.00, and a low forecast of $21.00.
The average price target represents a +191.10% change from the last price of $8.76.
Highest Price Target
$30.00
Average Price Target
$25.50
Lowest Price Target
$21.00
OCUL Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Ocular Therapeutix, Inc. in the past 3 months
EPS Estimates — OCUL
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.22
vs Est –$1.18
▼ 3.3% off
2025
Actual –$1.42
vs Est –$1.45
▲ 2.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — OCUL
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.064B
vs Est $0.064B
▼ 0.0% off
2025
Actual $0.052B
vs Est $0.055B
▼ 5.7% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
